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A B S T R A C T
Therapeutic Drug Monitoring (TDM) is increasingly recommended to ensure the correct drug dose
thereby minimizing adverse events and maximizing regimen efficacy. To facilitate implementation in TB
programs, a framework for TDM is urgently needed. TDM is only useful for dose optimization if a patient
is on an appropriate regimen guided by drug susceptibility testing. TDM using a targeted approach
selecting patients with risk factors for suboptimal drug exposure (e.g. diabetes) or not responding to
treatment for drugs with a clear concentration-response relationship may provide the best value for
money. Semiquantitative point-of-care tests for detection of low or high drug concentration should be
implemented at community level while quantitative assays can be performed at regional or central level.
Expanding PK/PD research followed by clinical trials including both clinical outcome as well as cost-
effectiveness will increase the level of evidence supporting TDM.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Traditionally, tuberculosis (TB) control programmes focus their
resources on rapid diagnosis and effective treatment to ensure
individual benefit to the patient and break the chain of
transmission (if the patient is infectious) (Migliori et al. 2019;
Nahid et al. 2019). In spite of a comprehensive effort of the
international community, the treatment success rates of multi-
drug-resistant (MDR)-TB are globally in the order of 55%, (lower on
extensively drug-resistant (XDR)-TB cases) although recent evi-
dence suggests that the use of new drugs (e.g. bedaquiline)
(Borisov et al. 2017) can increase it to 80% and beyond even outside
clinical trials (Ahmad et al. 2018). Recently, more attention has
been paid to monitoring and management of adverse events,* Corresponding author at: Sydney Pharmacy School, Faculty of Medicine and
Health, The University of Sydney, Camperdown, NSW 2006, Australia.
E-mail address: johannes.alffenaar@sydney.edu.au (J.-W.C. Alffenaar).
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1201-9712/© 2020 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2019; Borisov et al. 2019).
Recently the concept of ‘precision medicine’ (Alffenaar et al.
2019) has been a subject of discussion: more and more new
guidelines (Nahid et al. 2017, 2019) are recommending
individualised treatment based on drug-susceptibility testing
(DST) results and DST ideally coupled with actionable knowl-
edge of antibiotic pharmacokinetics (PK) and pharmacodynam-
ics (PD). The Pharmacology Committee of the Global
Tuberculosis Network (GTN) (Alffenaar et al. 2019) has worked
intensively to promote Therapeutic Drug Monitoring (TDM), a
technique which is rendering it increasingly easy to dose anti-TB
drugs in the blood, to ensure the correct drug dose (not more,
not less), minimizing adverse events and maximizing regimen
efficacy.
The aim of the manuscript is to discuss the programmatic
feasibility of TDM (Ghimire et al. 2016) taking into account the
specific features and interplay of pathogen, patient and drug and
drug assay characteristics used to perform TDM.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
ngen from ClinicalKey.com by Elsevier on April 02, 2020.
. Copyright ©2020. Elsevier Inc. All rights reserved.
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DST is essential for ensuring that a patient is on an appropriate
regimen and preventing drug resistance development. Phenotypic
DST is however costly (requiring lab capacity), technically
demanding (non-viable samples, contamination and interpreta-
tion can lead to delays) and time consuming (1–2 weeks or longer).
In order to help guide physicians more rapidly, genotypic and
whole genome sequencing methods are being employed and may
be able to detect mutations where there is no correlation to MICs.
The WHO endorses both phenotypic and genotypic DST (World
Health Organization 2019), the GeneXpert Ultra is a rapid
molecular test (result in under 80 min), to triage patients between
RR-TB and DS-TB. A molecular line probe assay GenoType MTBDRsl
V2 can detect resistance to first (isoniazid, rifampicin, ethambutol
and pyrazinamide) and second line drugs (fluoroquinolones,
ethionamide/prothionamide and aminoglycosides) in order to
help triage patients onto the shorter WHO regimen, however
changes in regimen (linezolid, bedaquiline and clofazimine
replacing aminoglycosides and ethionamide) means that we will
need newer tests that can triage MDR/XDR TB patients more
effectively.
Phenotypic susceptibility allows for MIC determination, which
can be combined with AUC TDM to determine the appropriate dose
of an individual drug. Virtual MICs based on association of
phenotypic susceptibility with single or multiple mutations is
developing and it is possible to base treatment on the following
genotypic DST results (Kambli et al. 2015b; Miotto et al. 2017); for
rifampicin some mutations suggest that higher doses of rifampicin
>20 mg/kg may be considered, moreover rifabutin may retain
activity and rifampicin 35 mg/kg may be effective. Normal dose
Isoniazid can be given in the presence of inhA mutations (at normal
doses), requiring higher doses in the presence of katG), with both
inhA and katG, isoniazid should not be used (Cambau et al. 2015;
Rieder and Van Deun 2017). Fluoroquinolones also appear to have
resistance mutations that may characterise low resistance MIC <1
and high resistance mutations (Kambli et al. 2015a; Chien et al.
2016). Moxifloxacin can therefore be expected to have activity at a
higher dose of 800 mg a day in the presence of low-level resistance.
We have now identified several mutations correlated with
resistance. We will continue to need the phenotypic MIC testing in
certain cases when lacking molecular or sequencing results or
when discrepancies or unknown mutations are encountered
(Faksri et al. 2019). Furthermore the CRyPTIC consortium are
using next generation sequencing to evaluate genetic resistance
prediction by cataloguing resistant strains; this may lead to rapid
universal drug susceptibility testing (DST).
Host (host characteristics affecting pharmacokinetics)
TDM is recommended for patients with severe gastrointestinal
abnormalities, diabetes mellitus (DM), HIV, renal impairment or on
dialysis and patients with inadequate treatment response (Nahid
et al. 2017, 2019). DM often causes gastroparesis, which may result
in malabsorption or delayed absorption. Although impact of DM on
drug exposure has been a subject of debate, two recent studies
showed reduced exposure to first line drugs and moxifloxacin in
patients with TB and DM (Dekkers et al. 2019; Mtabho et al. 2019).
This reduced exposure was due to increased drug clearance and
partly due to malabsorption.
A recently published systematic review of the effect of HIV
infection on PK in TB patients showed no consistent results
(Daskapan et al. 2019). For rifampicin most studies showed low
total exposure in all TB patients, unrelated to HIV infection. Several
studies showed significant lower AUC values for RIF in HIV infected
TB patients. However one study also showed a significant higherDownloaded for Anonymous User (n/a) at University of Gron
For personal use only. No other uses without permissionAUC in HIV positive TB patients compared to HIV negative TB
patients. For isoniazid none of the studies showed significant
differences in AUC between HIV positive and HIV negative TB
patients. For pyrazinamide some studies showed significantly
lower AUC in HIV positive TB patients, while other studies showed
no difference.
Other possible indications to perform TDM are patients who are
malnourished or who are pregnant. Malnutrition due to TB itself
leads to a decreased fat-free mass and is often related to
malabsorption as well. The first might lead to a change in volume
of distribution and the latter might cause low exposure. Studies on
this topic are still lacking (Ter Beek et al. 2019). Pregnancy leads to
an increased volume of body fluid, which causes an increase of the
volume of distribution of drugs and that can lead to a decreased
peak drug concentration. Furthermore pregnancy may enhance the
elimination of drugs (Van Kampenhout et al. 2017).
Drug
Dose-exposure-response relationships of TB drugs are affected
by mycobacterial and host-related variability. These include
lineage-specific factors, growth phase, phenotypic and genetic
susceptibility, location and extent of TB, cavity formation, host
immune function, renal and hepatic function (Alffenaar et al.
2019).
American Thoracic Society (ATS) guidelines recommend TDM in
case of treatment with second-line drugs, specifically for linezolid
and cycloserine/terizidone (in renal impairment) (Nahid et al.
2019). Updated WHO guidelines also support TDM for second line
drugs including linezolid, fluoroquinolones and injectables (i.e.
aminoglycosides) (World Health Organization 2019).
Toxicity due to drugs such as ethambutol (ocular toxicity),
isoniazid (peripheral neuropathy), pyrazinamide (hepatotoxicity),
linezolid (haematological toxicity and peripheral neuropathy) and
fluoroquinolone (QT prolongation) are drug concentration-depen-
dent. ATS guidelines explicitly state avoiding cycloserine concen-
trations >35 mg/L to prevent CNS toxicity (Nahid et al. 2019).
Sub-optimal drug exposure can lead to acquired resistance,
delayed culture conversion or relapse (Pasipanodya et al. 2013).
Efficacy is often correlated with drug exposure, specifically with
pharmacodynamically linked markers such as AUC0-24/MIC (most
commonly), Cmax/MIC or T/MIC (Alffenaar et al. 2019). Such PK/PD
targets are largely derived from the Hollow Fiber System Model of TB
and Monte Carlo simulations. Optimal efficacy of linezolid appears to
be driven by AUC0-24/MIC >100 (Bolhuis et al. 2018). AUC0-24/MIC
ratio is also the best predictor of efficacy for fluoroquinolones (Van
den Elsen et al. 2018; van den Elsen et al. 2019).
Limited sampling strategies have become available for a
number of TB drugs such as isoniazid, rifampicin, pyrazinamide,
ethambutol, linezolid, moxifloxacin and levofloxacin, and will
allow accurate estimation of total drug exposures with a limited
number of samples (Kamp et al. 2017; Van den Elsen et al. 2018;
van den Elsen et al. 2019). For example, moxifloxacin AUC could be
accurately estimated with 2 samples, i.e. a trough sample
combined with a sample at 4 or 6 h after drug intake (van den
Elsen et al. 2019).
Assay
TDM requires an analytical method suitable for fast and
accurate quantification of anti-TB drug concentrations. Tradition-
ally high-performance liquid chromatography (HPLC) with UV
detection has been used to quantify drug concentrations. The
extensive sample preparation, long run times in combination with
cold chain shipments to central laboratories have been a major
hurdle for broad scale implementation of TDM. The introduction ofingen from ClinicalKey.com by Elsevier on April 02, 2020.
. Copyright ©2020. Elsevier Inc. All rights reserved.
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spectrometry (LC–MS/MS) enabled detection of drugs in very small
samples (<50 mL) and allowed the development of assays suitable
for measurement of drug concentrations in dried blood spots (Vu
et al. 2011; Veringa et al. 2016). Dried blood spots samples show an
increased stability compared to plasma or serum and could
therefore be shipped at room temperature and even by mail. Due to
high purchase costs and need for skilled technicians, such methods
can only be operated at a central level. The lack of awareness in the
community in combination with long turnaround time hindered
broad scale implementation (Alffenaar et al. 2019). Therefore,
there is an urgent need for a semi-quantitative test to support
physicians to make informed decisions on drug dosing (Alffenaar
et al. 2019). Such a test should be able to distinguish between low,Table 1
Therapeutic drug monitoring in a programmatic setting.
X indicated the most suitable assay for each clinical situation. The gre
central) where the assay should be made available for optimal use. T
Downloaded for Anonymous User (n/a) at University of Groning
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(serum/plasma) like saliva or urine could be used as they can be
easily collected (non-invasive) and reflect the drug concentration
in the body. Simple UV spectrophotometers could be employed to
measure drug concentrations in these matrixes. The advantage of
such easy to operate equipment is low purchase costs, allowing use
in the community.
Programmatic treatment — TDM
A targeted approach to implement TDM in a programmatic
setting is likely more effective and affordable than TDM for every
patient. A targeted approach relies on selection of patients that
may benefit from TDM. Host, pathogen and drug related factors cany shaded areas indicate the location (e.g. community, regional or
DM = therapeutic drug monitoring.
en from ClinicalKey.com by Elsevier on April 02, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.
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Alffenaar et al. 2019). Host factors associated with low drug
exposure, less susceptible pathogens, and drugs with a high
variability in drug exposure should be included to decide on the
use of TDM. Based on frequency of use, level of expertise and
facilities required to operate an assay and costs, we propose 3
levels of TDM (Ghimire et al. 2016; Alffenaar et al. 2019).
1) Community level; easy to access screening UV assays (saliva/
urine) for key first (INH, RIF, PZA) and second line drugs (FQ,
LZD) to determine low, normal and high drug exposure.
2) Regional level; quantitative assays, either HPLC-UV or entry
level LCMSMS for key first and second line drugs should be
available to perform individualized dosing in those patients
with known low drug exposure and patients with high drug
exposure in combination with signs of adverse effects.
3) Central level; quantitative assays using advanced LCMSMS can
be used for measuring drug concentration in dried samples
(blood, saliva) shipped by mail from the community.
With the 3 levels of TDM we recommend to make use of the
available expertise. Results obtained from screening assays in the
community should be easily translated in uniform clinical
decisions, while results from quantitative assays at the regional
level should be accompanied by individualized dose recommen-
dations. Screening assays could be of value as well for patients on
preventative treatment as it can help to detect malabsorption in
patients with, e.g., Crohn’s disease or to help assess adherence. For
very difficult to treat cases requiring TDM for less frequently
assayed drugs it could be recommended that these cases will be
discussed in a national Consilium with appropriate expertise. At
the central level, quality assurance for TDM at the programmatic
level should also be accommodated, including proficiency testing
programs and training of staff. A centralized model (Degeling et al.
2020) for TDM, with a reference center with adequate expertise,
will likely be better equipped (e.g. funding) for implementation of
innovative techniques in TDM (Table 1).
Knowledge gaps — what to do next
Adequate drug selection and precision dosing can be considered
the best practice to increase response to therapy, reduce risk of
acquired drug resistance and prevent adverse drug reactions. To
support precision dosing for all TB drugs in vitro PK/PD studies
using a hollow fiber system model of tuberculosis have to be
performed and subsequent results have to be validated in clinical
trials for those drugs where evidence is lacking. The next step is to
perform a randomized controlled trial to compare TDM with
standard of care to show the benefits of precision dosing. Although
a double-blind design may not be feasible due to technical
complexity appropriate control mechanisms can be included in the
trial design to minimize bias and confounding factors. Patients for
whom TDM is already being recommended in current guidelines
(Nahid et al. 2019; World Health Organization 2019) should be
prioritized. The primary end-point of a TDM trial should not focus
on a single clinical end-point such as prevention of acquired
resistance but on the cost-effectiveness of the optimized clinical
management of TB patients. If costs related to the clinical
management of TB can be reduced, a programmatic implementa-
tion is likely to be more feasible. To facilitate broad scale
programmatic implementation, robust and affordable point-of-
care tests have to be developed. Once evidence and tests are
available, guidance documents (including information on evi-
dence, cost-effectiveness, technical aspects of TDM) on local
implementation should be issued like in the past for new tests orDownloaded for Anonymous User (n/a) at University of Gron
For personal use only. No other uses without permissiondrugs. Effectiveness of the use of TDM should subsequently be
evaluated in a real-life setting.
Conclusion
Considerable progress has been in precision medicine for TB
through drug selection based on molecular diagnostic tests and
drug exposure evaluation in patients at risk for low or high
drug exposure. Expanding in vitro PK/PD research followed by
clinical trials will complete the evidence supporting TDM.
Development of point-of-care tests and TDM in a multistep
approach will provide the framework for testing cost-effectiveness
of programmatic TDM. Following favourable trial results, guidance
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